Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,773.00
-24.00 (-1.34%)
Apr 29, 2026, 3:30 PM KST
-52.78%
Market Cap 30.66B
Revenue (ttm) 1.95B
Net Income (ttm) -10.93B
Shares Out 17.29M
EPS (ttm) -938.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 154,016
Average Volume 315,022
Open 1,802.00
Previous Close 1,797.00
Day's Range 1,750.00 - 1,841.00
52-Week Range 1,301.00 - 4,120.00
Beta n/a
RSI 68.97
Earnings Date Apr 13, 2026

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 373110
Full Company Profile

Financial Performance

In 2025, Xcell Therapeutics's revenue was 1.95 billion, an increase of 0.76% compared to the previous year's 1.93 billion. Losses were -10.93 billion, 14.5% more than in 2024.

Financial Statements

News

There is no news available yet.